1
|
Marques A, Rieu I, Pereira B, Castelnovo G, Fluchère F, Laurencin C, Degos B, Poujois A, Kreisler A, Sangla S, Tir M, Benatru I, Blanchet-Fourcade G, Guehl D, Gayraud D, Tatu L, Tranchant C, Simonetta-Moreau M, Durif F. French validation of the Quality of life in Essential Tremor Questionnaire (QUEST) and the Essential Tremor Embarrassment Assessment (ETEA). Rev Neurol (Paris) 2023; 179:1128-1133. [PMID: 37735016 DOI: 10.1016/j.neurol.2023.03.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Revised: 01/30/2023] [Accepted: 03/31/2023] [Indexed: 09/23/2023]
Abstract
Two scales have been developed and validated in English to evaluate the impact of tremor on daily life, namely Quality of life in Essential Tremor Questionnaire (QUEST) and Essential Tremor Embarrassment Assessment (ETEA). The psychometric properties of the French version of these two scales were assessed for 117 patients with head tremor. Both scales showed excellent acceptability, very good internal consistency (Cronbach's alpha coefficient>0.8) and reproducibility (Lin concordance coefficient>0.8), satisfactory external validity and satisfactory sensitivity to change. In conclusion, the French versions of QUEST and ETEA are comprehensive, valid and reliable instruments for assessing patients with head tremor.
Collapse
Affiliation(s)
- A Marques
- Department of Neurology, CHU de Clermont-Ferrand, université Clermont-Auvergne, CNRS, institut Pascal, place Henri-Dunant, 63000 Clermont-Ferrand, France.
| | - I Rieu
- Department of Neurology, CHU de Clermont-Ferrand, université Clermont-Auvergne, CNRS, institut Pascal, place Henri-Dunant, 63000 Clermont-Ferrand, France
| | - B Pereira
- Clinical Research Department, Biostatistics Unit, CHU de Clermont-Ferrand, 63000 Clermont-Ferrand, France
| | - G Castelnovo
- Service de neurologie, centre hospitalier universitaire Caremeau, 30029 Nîmes, France
| | - F Fluchère
- Department of Neurology and Movement Disorders, Timone Hospital, Aix-Marseille université, 13005 Marseille, France
| | - C Laurencin
- Lyon Neuroscience Research Center, Inserm, U 1028, CNRS, UMR 5292, Neuroplasticity and Neuropathology of Olfactory Perception team, université de Lyon, université Claude-Bernard Lyon 1, 69000 Lyon, France; Service de neurologie C, hospices civils de Lyon (HCL), Pierre-Wertheimer Neurological Hospital, 69000 Lyon, France
| | - B Degos
- Service de neurologie, hôpital Avicenne, AP-HP, université Sorbonne Paris Nord, 93000 Bobigny, France; Dynamics and Pathophysiology of Neuronal Networks Team, Center for Interdisciplinary Research in Biology, collège de France, CNRS UMR7241/Inserm U1050, université Paris sciences & lettres (PSL), 75005 Paris, France
| | - A Poujois
- Service de neurologie, hôpital Fondation Adolphe de Rothschild, 75019 Paris, France
| | - A Kreisler
- Service de neurologie A, Movement Disorders Unit, CHU de Lille, 59037 Lille, France
| | - S Sangla
- Unité Parkinson, hôpital Adolphe de Fondation Rothschild, 75019 Paris, France
| | - M Tir
- Department of Neurology and the Department of Neurosurgery, Expert Centre for Parkinson's Disease, Amiens University Hospital, 80054 Amiens, France; EA 4559 laboratoire de neurosciences fonctionnelles et pathologie (LNFP), University of Picardy Jules-Verne (UPJV), 80054 Amiens, France
| | - I Benatru
- Department of Neurology, University Hospital of Poitiers, 86000 Poitiers, France; Centre d'investigation clinique CIC1402, CHU de Poitiers, University of Poitiers, Inserm, 86000 Poitiers, France
| | | | - D Guehl
- Centre hospitalier universitaire de Bordeaux, institut des maladies neurodégénératives, CNRS, University of Bordeaux, 33000 Bordeaux, France
| | - D Gayraud
- Service de neurologie, centre hospitalier intercommunal Aix-Pertuis, site d'Aix-en-Provence, avenue des Tamaris, 13616 Aix-en-Provence, France
| | - L Tatu
- Department of Neuromuscular Diseases and Department of Anatomy, CHRU de Besançon, University of Franche-Comté, 25030 Besançon, France
| | - C Tranchant
- Department of Neurology, CHU Hautepierre, 67000 Strasbourg, France
| | - M Simonetta-Moreau
- Department of Neurology, Clinical Investigation Center (CIC 1436), Toulouse University Hospital, Inserm (ToNIC 1214), 31059 Toulouse, France
| | - F Durif
- Department of Neurology, CHU de Clermont-Ferrand, université Clermont-Auvergne, CNRS, institut Pascal, place Henri-Dunant, 63000 Clermont-Ferrand, France
| |
Collapse
|
2
|
Mahoui S, Belkhamsa O, Ait Kaci I, Abada Bendib M, Castelnovo G. Leber optic hereditary neuropathy plus dystonia. Rev Neurol (Paris) 2019; 175:483-484. [PMID: 31221418 DOI: 10.1016/j.neurol.2018.12.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Revised: 12/13/2018] [Accepted: 12/14/2018] [Indexed: 10/26/2022]
Affiliation(s)
- S Mahoui
- Department of neurology, university hospital of Ben Aknoun, Algiers, Algeria.
| | - O Belkhamsa
- Department of neurology, university hospital Nedir Mohamed, Tizi Ouzou, Algeria
| | - I Ait Kaci
- Department of neurology, university hospital of Ben Aknoun, Algiers, Algeria
| | - M Abada Bendib
- Department of neurology, university hospital of Ben Aknoun, Algiers, Algeria
| | - G Castelnovo
- Department of neurology, university hospital of Nîmes, Nîmes, France
| |
Collapse
|
3
|
Codjia P, Ayrignac X, Mochel F, Mouzat K, Carra-Dalliere C, Castelnovo G, Ellie E, Etcharry-Bouyx F, Verny C, Belliard S, Hannequin D, Marelli C, Nadjar Y, Le Ber I, Dorboz I, Samaan S, Boespflug-Tanguy O, Lumbroso S, Labauge P. Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia: An MRI Study of 16 French Cases. AJNR Am J Neuroradiol 2018; 39:1657-1661. [PMID: 30115677 DOI: 10.3174/ajnr.a5744] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2018] [Accepted: 05/01/2018] [Indexed: 11/07/2022]
Abstract
Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia is an autosomal dominant leukoencephalopathy related to CSF1R gene mutations. A growing number of clinicoradiologic phenotypes have been described. In this study, we analyzed brain imaging findings in 16 patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia to refine radiologic diagnostic clues. T2/FLAIR white matter hyperintensities were present in all patients with frontal or frontoparietal predilection, with asymmetric distribution in more than one-third. Brain atrophy and callosal involvement were almost constant, and corticospinal tract involvement was frequent. Moreover, deep white matter hyperintense dots on DWI and deep punctate calcifications on CT were often found. Conversely, deep gray matter nuclei, external capsules, and brain stem were rarely involved. Our series emphasized the great variability of MR imaging findings seen in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. A complete imaging screening including DWI, T2*, and CT is mandatory to accurately assess patients with suspected inherited adult-onset leukoencephalopathy.
Collapse
Affiliation(s)
- P Codjia
- From the Department of Neurology (P.C., X.A., C.C.-D., C.M., P.L.), Montpellier University Hospital, Montpellier, France
| | - X Ayrignac
- From the Department of Neurology (P.C., X.A., C.C.-D., C.M., P.L.), Montpellier University Hospital, Montpellier, France
| | - F Mochel
- Genetics (F.M.), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Paris, France
| | - K Mouzat
- Departments of Biochemistry and Molecular Biology (K.M., S.L.)
| | - C Carra-Dalliere
- From the Department of Neurology (P.C., X.A., C.C.-D., C.M., P.L.), Montpellier University Hospital, Montpellier, France
| | - G Castelnovo
- Neurology (G.C.), Nîmes University Hospital, Nîmes, France
| | - E Ellie
- Department of Neurology (E.E.), Côte Basque Hospital, Bayonne, France
| | - F Etcharry-Bouyx
- Department of Neurology (F.E.-B., C.V.), Angers University Hospital, Angers, France
| | - C Verny
- Department of Neurology (F.E.-B., C.V.), Angers University Hospital, Angers, France
| | - S Belliard
- Department of Neurology (S.B.), Rennes University Hospital, Rennes, France
| | - D Hannequin
- Department of Neurology (D.H.), Rouen University Hospital, Rouen, France
| | - C Marelli
- From the Department of Neurology (P.C., X.A., C.C.-D., C.M., P.L.), Montpellier University Hospital, Montpellier, France
| | - Y Nadjar
- Departments of Neurology (Y.N., I.L.B.)
| | - I Le Ber
- Departments of Neurology (Y.N., I.L.B.)
| | - I Dorboz
- Department of Neuropediatrics and Metabolic Disorders (I.D., S.S., O.B.-T.), Assistance Publique-Hôpitaux de Paris, Robert Debré University Hospital, Paris, France
| | - S Samaan
- Department of Neuropediatrics and Metabolic Disorders (I.D., S.S., O.B.-T.), Assistance Publique-Hôpitaux de Paris, Robert Debré University Hospital, Paris, France
| | - O Boespflug-Tanguy
- Department of Neuropediatrics and Metabolic Disorders (I.D., S.S., O.B.-T.), Assistance Publique-Hôpitaux de Paris, Robert Debré University Hospital, Paris, France
| | - S Lumbroso
- Departments of Biochemistry and Molecular Biology (K.M., S.L.)
| | - P Labauge
- From the Department of Neurology (P.C., X.A., C.C.-D., C.M., P.L.), Montpellier University Hospital, Montpellier, France
| |
Collapse
|
4
|
Laplaud DA, Barbin L, Casey R, Debouverie M, Vukusic S, Labauge P, Brassat D, Wiertlewski S, De Seze J, Edan G, Brochet B, Moreau T, Berger E, Clavelou P, Castelnovo G, Ciron J, Pelletier J, Bourre B, Lubetzki C, Al Khedr A, Vermersch P, Lebrun-Frenay C, Defer G, Tourbah A, Camdessanche JP, Stankoff B, Labeyrie C, Patry I, Creange A, Gout O, Heinzlef O, Casez O, Magy L, Guennoc AM, De Broucker T, Nifle C, Dupel-Pottier C, Leray E, Rollot F, Foucher Y. Efficacité comparée du Teriflunomide et du Dimethyl-Fumarate : une étude observationnelle française multicentrique. Rev Epidemiol Sante Publique 2018. [DOI: 10.1016/j.respe.2018.04.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022] Open
|
5
|
Lavie C, Rollot F, Durand-Dubief F, Marignier R, Ionescu I, Casey R, Moreau T, Tourniaire P, Hutchinson M, D’Hooghe MB, Laplaud DA, Clavelou P, De Sèze J, Debouverie M, Brassat D, Pelletier J, Lebrun-Frenay C, Le Page E, Castelnovo G, Berger E, Hautecoeur P, Heinzlef O, Durelli L, Clerico M, Trojano M, Patti F, Vukusic S, Alpérovitch A, Carton H, d’Hooghe M, Hommes O, Hutchinson M, Adeleine P, Biron A, Cortinovis-Tourniaire P, Grimaud J, Hours M, Moreau T, Vukusic S, Confavreux C, Chauplannaz G, Confavreux C, Cortinovis-Tourniaire P, Grimaud J, Latombe D, Moreau T, Clanet M, Lau G, Rumbach L, Goas J, Rouhart F, Mazingue A, Roullet E, Madigand M, Hautecoeur P, Brunet P, Edan G, Allaire C, Riffault G, Leche J, Benoit T, Simonin C, Ziegler F, Baron J, Rivrain Y, Dumas R, Loche D, Bourrin J, Huttin B, Delisse B, Gibert I, Boulay C, Verceletto M, Durand G, Bonneviot G, Gil R, Hedreville M, Belair C, Poitevin R, Devoize J, Wyremblewski P, Delestre F, Setiey A, Comi G, Filippi M, Ghezzi A, Martinelli V, Rossi P, Zaffaroni M, Tola M, Amato M, Fioretti C, Meucci G, Inglese M, Mancardi G, Gambi D, Thomas A, Cavazzuti M, Citterio A, Heltberg A, Hansen H, Fernandez O, Romero F, Arbizu T, Hernandez J, De Andres de Frutos C, Geffner Sclarky D, Aladro Benito Y, Reyes Yanes P, Aguilar M, Burguera J, Yaya R, Bonakim Dib W, Arzua-Mouronte D, d’Hooghe M, Sindic C, Carton H, Medaer R, Roose H, Geens K, Guillaume D, Van Zandycke M, Janssens J, Cornette M, Mol L, Weilbach F, Flachenecker P, Hartung H, Haas J, Tendolkar I, Sindrn E, Kölmel H, Reichel D, Rauch M, Preuss S, Poser S, Mauch E, Strausser-Fuchs S, Kolleger H, Hawkins S, Howell S, Rees J, Thompson A, Johnson M, Boggild M, Gregory R, Bates D, Bone I, Hutchinson M, Polman C, Frequin S, Jongen P, Hommes O, Correia de Sa J, Rio M, Huber S, Lechner-Scott J, Kappos L, Ionescu I, Cornu C, Confavreux C, Vukusic S, El-Etr M, Baulieu E, El-Etr M, Schumacher M, Ionescu I, Confavreux C, Cornu C, Vukusic S, Hartung H, Miller D, Hutchinson M, Pugeat M, d’Archangues C, Conard J, Ménard J, Sitruk-Ware R, Pelissier C, Dat S, Belaïsch-Allard J, Athéa N, Büschsenschutz D, Lyon-Caen O, Gonsette R, Boissel J, Ffrench P, Durand-Dubief F, Cotton F, Pachai C, Bracoud L, Vukusic S, Ionescu I, Androdias G, Marignier R, Chauplannaz G, Laplaud D, Wiertlewski S, Lanctin-Garcia C, Moreau T, Couvreur G, Madinier G, Clavelou P, Taithe F, Aufauvre D, Guy N, Ferrier A, De Sèze J, Collongues N, Debouverie M, Viala F, Brassat D, Gerdelat-Mas A, Henry P, Pelletier J, Rico-Lamy A, Lebrun-Frenay C, Lepage E, Deburghraeve V, Edan G, Castelnovo G, Berger E, Hautecoeur P, Blondiau M, Heinzlef O, Coustans M, Clerc C, Rieu L, Lauxerois M, Hinzelin G, Ouallet J, Minier D, Vion P, Gromaire-Fayolle N, Derache N, Thouvenot E, Sallansonnet-Froment M, Tourniaire P, Toureille L, Borgel F, Stankoff B, Grimaud J, Moroianu C, Guennoc A, Tournier-Gervason C, Peysson S, Trojano M, Patti F, D’Amico E, Motti L, Zaffaroni M, Durelli L, Tavella A. Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. Mult Scler 2018; 25:591-600. [DOI: 10.1177/1352458518763080] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Background: Obstetrical analgesia remains a matter of controversy because of the fear of neurotoxicity of local anesthetics on demyelinated fibers or their potential relationship with subsequent relapses. Objective: To assess the impact of neuraxial analgesia on the risk of relapse during the first 3 months post-partum, with a focus on women who experienced relapses during pregnancy. Methods: We analyzed data of women followed-up prospectively during their pregnancies and at least 3 months post-partum, collected in the Pregnancy in Multiple Sclerosis (PRIMS) and Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPARTMUS) studies between 1992–1995 and 2005–2012, respectively. The association of neuraxial analgesia with the occurrence of a post-partum relapse was estimated by logistic regression analysis. Results: A total of 389 women were included, 215 from PRIMS and 174 from POPARTMUS. In total, 156 women (40%) had neuraxial analgesia. Overall, 24% experienced a relapse during pregnancy and 25% in the 3 months post-partum. Women with a pregnancy relapse were more likely to have a post-partum relapse (odds ratio (OR) = 1.83, p = 0.02), independently of the use of neuraxial analgesia. There was no association between neuraxial analgesia and post-partum relapse (OR = 1.08, p = 0.78). Conclusion: Neuraxial analgesia was not associated with an increased risk of post-partum relapses, whatever multiple sclerosis (MS) activity during pregnancy.
Collapse
Affiliation(s)
- Caroline Lavie
- Service de Neurologie A, Hôpital Pierre Wertheimer,
Hospices Civils de Lyon, Lyon, France
| | - Fabien Rollot
- Observatoire Français de la Sclérose en Plaques (OFSEP),
Lyon, France
| | | | - Romain Marignier
- Service de Neurologie A, Hôpital Pierre Wertheimer,
Hospices Civils de Lyon, Lyon, France/Centre de Recherche en Neurosciences de Lyon,
INSERM U1028, CNRS UMR5292, Equipe Neuro-Oncologie et Neuro-Inflammation, Lyon, France;
Université de Lyon 1, Lyon, France
| | - Iuliana Ionescu
- Service de Neurologie A, Hôpital Pierre Wertheimer,
Hospices Civils de Lyon, Lyon, France
| | - Romain Casey
- Observatoire Français de la Sclérose en Plaques (OFSEP),
Lyon, France
| | - Thibault Moreau
- Department of Neurology, EA4184, University Hospital of
Dijon, Dijon, France
| | | | - Michael Hutchinson
- School of Medicine and Medical Science, University College
Dublin, Dublin, Ireland/Department of Neurology, St Vincent’s University Hospital,
Dublin, Ireland
| | - Marie Béatrice D’Hooghe
- National MS Center Melsbroek, Melsbroek, Belgium; Center
for Neurosciences, Vrije Universiteit Brussel (VUB), Brussel, Belgium
| | - David-Axel Laplaud
- Service de Neurologie, CHU de Nantes, CIC015 INSERM,
Nantes, France/INSERM UMR1064, Nantes, France
| | - Pierre Clavelou
- Service de Neurologie, CHU de Clermont-Ferrand,
Clermont-Ferrand, France/INSERM UMR1107, Clermont Université, Université d’Auvergne,
Neuro-Dol, Clermont-Ferrand, France
| | - Jérôme De Sèze
- Department of Neurology, Clinical Investigation Center
INSERM 1434, Hôpitaux Universitaires de Strasbourg, FMTS INSERM 1119, Strasbourg,
France
| | - Marc Debouverie
- EA 4360 APEMAC, University of Lorraine, Nancy,
France/Department of Neurology, Nancy University Hospital, Nancy, France
| | - David Brassat
- Pôle Neurosciences, CHU Toulouse Purpan, Toulouse,
France/INSERM U1043, CNRS UMR 5282, Université Toulouse III, Toulouse, France
| | - Jean Pelletier
- Service de Neurologie, Hôpital de la Timone, Pôle de
Neurosciences Cliniques, AP-HM, Aix-Marseille Université, Marseille, France/CNRS,
Aix-Marseille Université, CRMBM UMR7339, Marseille, France
| | | | - Emmanuelle Le Page
- Clinical Neuroscience Centre, CIC-P 1414 INSERM, Rennes
University Hospital, Rennes, France
| | | | - Eric Berger
- Department of Neurology, CHU Besançon, Besançon,
France
| | - Patrick Hautecoeur
- Service de Neurologie, Groupement des Hôpitaux de
l’Institut Catholique de Lille, Lille, France
| | - Olivier Heinzlef
- Department of Neurology, Hôpital CHI de
Poissy/Saint-Germain-en-Laye, Paris, France
| | - Luca Durelli
- Division of Neurology, Department of Clinical and
Biological Sciences, University of Torino, San Luigi Gonzaga University Hospital,
Orbassano, Italy
| | - Marinella Clerico
- Division of Neurology, Department of Clinical and
Biological Sciences, University of Torino, San Luigi Gonzaga University Hospital,
Orbassano, Italy
| | - Maria Trojano
- Department of Basic Medical Sciences, Neuroscience and
Sense Organs, University of Bari Aldo Moro, Bari, Italy
| | - Francesco Patti
- Department of Medical and Surgical Sciences, and Advanced
Technologies, G.F. Ingrassia, Multiple Sclerosis Center, University of Catania, Catania,
Italy
| | - Sandra Vukusic
- Service de Neurologie A, Hôpital Pierre Wertheimer,
Hospices Civils de Lyon, Lyon, France/Observatoire Français de la Sclérose en Plaques
(OFSEP), Lyon, France/Centre de Recherche en Neurosciences de Lyon, INSERM U1028, CNRS
UMR5292, Equipe Neuro-Oncologie et Neuro-Inflammation, Lyon, France/Université de Lyon
1, Lyon, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
|
7
|
Nerrant E, Thouvenot E, Castelnovo G. Severe bradycardia: An unreported adverse infusion-associated reaction (IAR) with alemtuzumab. Rev Neurol (Paris) 2017; 173:175-176. [PMID: 28320519 DOI: 10.1016/j.neurol.2017.02.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2016] [Revised: 10/27/2016] [Accepted: 02/22/2017] [Indexed: 11/25/2022]
Affiliation(s)
- E Nerrant
- CHU de Nîmes, Department of Neurology, 9, place du Pr Robert Debré, Nîmes Cedex 9, 30029, France.
| | - E Thouvenot
- CHU de Nîmes, Department of Neurology, 9, place du Pr Robert Debré, Nîmes Cedex 9, 30029, France; Institut de Génomique Fonctionnelle, Neurosciences, 141, rue de la Cardonille, Montpellier cedex 5, 34294, France
| | - G Castelnovo
- CHU de Nîmes, Department of Neurology, 9, place du Pr Robert Debré, Nîmes Cedex 9, 30029, France
| |
Collapse
|
8
|
Dunet V, Deverdun J, Charroud C, Le Bars E, Molino F, Menjot de Champfleur S, Maury F, Charif M, Ayrignac X, Labauge P, Castelnovo G, Pinna F, Bonafe A, Geny C, Menjot de Champfleur N. Cognitive Impairment and Basal Ganglia Functional Connectivity in Vascular Parkinsonism. AJNR Am J Neuroradiol 2016; 37:2310-2316. [PMID: 27418471 DOI: 10.3174/ajnr.a4889] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2016] [Accepted: 06/05/2016] [Indexed: 01/14/2023]
Abstract
BACKGROUND AND PURPOSE Patients with vascular parkinsonism have higher cognitive decline and more basal ganglia lesions. We aimed to evaluate the relationship of cognitive impairment with functional connectivity between the basal ganglia and cingulate cortex in vascular parkinsonism. MATERIALS AND METHODS Thirty patients (8 with vascular parkinsonism and 22 with Parkinson disease) and 23 controls were enrolled. The Mattis Dementia Rating Scale and the Stroop Task were used to assess cognitive decline. MR imaging examinations included T1-MPRAGE, FLAIR, and resting-state fMRI sequences. MPRAGE was segmented to obtain basal ganglia and cingulate cortex volumes. FLAIR was segmented to obtain white matter hyperintensity lesion volume. Resting-state fMRI sequences were used to compare basal ganglia functional connectivity with the cingulate cortex between patients and controls. RESULTS Patients with vascular parkinsonism exhibited impaired attention, resistance to interference, and inhibitory control and an increased number of errors on the Stroop Task. They also had higher caudate nucleus and white matter hyperintensity lesion volumes, which were positively correlated (ρ = 0.75, P < .0001). Caudate nucleus functional connectivity with the perigenual anterior cingulate cortex was increased in patients with vascular parkinsonism compared with controls and patients with Parkinson disease, and it was positively correlated with the caudate nucleus volume (ρ = 0.44, P = .016). Caudate nucleus functional connectivity with the posterior cingulate cortex was decreased in patients with vascular parkinsonism compared with controls and negatively correlated with the number of errors on the Stroop test (ρ = -0.51, P = .0003). CONCLUSIONS In patients with vascular parkinsonism, cognitive decline could be related to changes of caudate nucleus functional connectivity with the cingulate cortex at resting-state, which may be induced by ischemia-related remodelling.
Collapse
Affiliation(s)
- V Dunet
- From the Departments of Neuroradiology (V.D., J.D., C.C., E.L.B., F.P, A.B., N.M.d.C.)
- Institut d'Imagerie Fonctionnelle Humaine, I2FH (V.D., J.D., C.C., E.L.B., F.P., A.B., N.M.d.C.), Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
- Department of Diagnostic and Interventional Radiology (V.D), Lausanne University Hospital, Lausanne, Switzerland
| | - J Deverdun
- From the Departments of Neuroradiology (V.D., J.D., C.C., E.L.B., F.P, A.B., N.M.d.C.)
- Institut d'Imagerie Fonctionnelle Humaine, I2FH (V.D., J.D., C.C., E.L.B., F.P., A.B., N.M.d.C.), Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
- Laboratoire Charles Coulomb (J.D., F.Molino), Centre National de la Recherche Scientifique Unite Mixte de Recherche 5221, Montpellier University, Montpellier, France
- Intrasense (J.D.), Montpellier, France
| | - C Charroud
- From the Departments of Neuroradiology (V.D., J.D., C.C., E.L.B., F.P, A.B., N.M.d.C.)
- Institut d'Imagerie Fonctionnelle Humaine, I2FH (V.D., J.D., C.C., E.L.B., F.P., A.B., N.M.d.C.), Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
- Neuropsychiatry: Epidemiological and Clinical Research (C.C.), Institut National de la Santé et de la Recherche Médicale, U1061, Montpellier University, La Colombiere Hospital, Montpellier, France
- Institut National de la Santé et de la Recherche Médicale (C.C.), U1198, Montpellier University, Montpellier, France
| | - E Le Bars
- From the Departments of Neuroradiology (V.D., J.D., C.C., E.L.B., F.P, A.B., N.M.d.C.)
- Institut d'Imagerie Fonctionnelle Humaine, I2FH (V.D., J.D., C.C., E.L.B., F.P., A.B., N.M.d.C.), Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
| | - F Molino
- Laboratoire Charles Coulomb (J.D., F.Molino), Centre National de la Recherche Scientifique Unite Mixte de Recherche 5221, Montpellier University, Montpellier, France
- Institut de Genomique Fonctionnelle (F.Molino), UMR 5203, Institut National de la Santé et de la Recherche Médicale, U661, Montpellier University, Montpellier, France
| | | | - F Maury
- Neurology (F.Maury, M.C., X.A., P.L., F.P., C.G.), Montpellier University Hospital Center, Gui de Chauliac Hospital, Montpellier, France
| | - M Charif
- Neurology (F.Maury, M.C., X.A., P.L., F.P., C.G.), Montpellier University Hospital Center, Gui de Chauliac Hospital, Montpellier, France
| | - X Ayrignac
- Neurology (F.Maury, M.C., X.A., P.L., F.P., C.G.), Montpellier University Hospital Center, Gui de Chauliac Hospital, Montpellier, France
| | - P Labauge
- Neurology (F.Maury, M.C., X.A., P.L., F.P., C.G.), Montpellier University Hospital Center, Gui de Chauliac Hospital, Montpellier, France
| | | | - F Pinna
- From the Departments of Neuroradiology (V.D., J.D., C.C., E.L.B., F.P, A.B., N.M.d.C.)
- Neurology (F.Maury, M.C., X.A., P.L., F.P., C.G.), Montpellier University Hospital Center, Gui de Chauliac Hospital, Montpellier, France
- Institut d'Imagerie Fonctionnelle Humaine, I2FH (V.D., J.D., C.C., E.L.B., F.P., A.B., N.M.d.C.), Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
| | - A Bonafe
- From the Departments of Neuroradiology (V.D., J.D., C.C., E.L.B., F.P, A.B., N.M.d.C.)
- Institut d'Imagerie Fonctionnelle Humaine, I2FH (V.D., J.D., C.C., E.L.B., F.P., A.B., N.M.d.C.), Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
- Team "Plasticity of Central Nervous System, Stem Cells and Glial Tumors" (A.B., N.M.d.C,), U1051, Institut of Neurosciences of Montpellier, Saint Eloi Hospital, Montpellier, France
| | - C Geny
- Neurology (F.Maury, M.C., X.A., P.L., F.P., C.G.), Montpellier University Hospital Center, Gui de Chauliac Hospital, Montpellier, France
- EuroMov (C.G.), Montpellier, France
- Movement to Health (C.G.), Montpellier University, Montpellier, France
| | - N Menjot de Champfleur
- From the Departments of Neuroradiology (V.D., J.D., C.C., E.L.B., F.P, A.B., N.M.d.C.)
- Institut d'Imagerie Fonctionnelle Humaine, I2FH (V.D., J.D., C.C., E.L.B., F.P., A.B., N.M.d.C.), Hôpital Gui de Chauliac, Centre Hospitalier Régional Universitaire de Montpellier, Montpellier, France
- Medical Imaging (N.M.d.C.), Caremeau University Hospital Center, Nimes, France
- Team "Plasticity of Central Nervous System, Stem Cells and Glial Tumors" (A.B., N.M.d.C,), U1051, Institut of Neurosciences of Montpellier, Saint Eloi Hospital, Montpellier, France
| |
Collapse
|
9
|
Schmidt S, Oschmann P, Neau J, Castelnovo G, Wang P, Barbato L, Mahadavan L. Walking, quality of life, and safety with prolonged-release fampridine treatment in clinical practice: Interim results of the liberate study. J Neurol Sci 2015. [DOI: 10.1016/j.jns.2015.08.135] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
10
|
Lippi A, Castelnovo G, Colombier L, Renard D. [An acute onset extrapyramidal, pyramidal, and cerebellar syndrome with eye movement dysfunction]. Rev Neurol (Paris) 2015; 171:898-9. [PMID: 26318889 DOI: 10.1016/j.neurol.2015.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2014] [Revised: 07/09/2015] [Accepted: 07/15/2015] [Indexed: 10/23/2022]
Affiliation(s)
- A Lippi
- Service de neurologie et faculté de médecine, hôpital Caremeau, CHU de Nîmes, place du Professeur-Robert-Debré, 30000 Nîmes, France.
| | - G Castelnovo
- Service de neurologie et faculté de médecine, hôpital Caremeau, CHU de Nîmes, place du Professeur-Robert-Debré, 30000 Nîmes, France
| | - L Colombier
- Service de neurologie et faculté de médecine, hôpital Caremeau, CHU de Nîmes, place du Professeur-Robert-Debré, 30000 Nîmes, France
| | - D Renard
- Service de neurologie et faculté de médecine, hôpital Caremeau, CHU de Nîmes, place du Professeur-Robert-Debré, 30000 Nîmes, France
| |
Collapse
|
11
|
Sijobert B, Lebrun C, Begel V, Verna C, Castelnovo G, Dalla Bella S, Coste C, Geny C. Interest of the task of “Stepping in place” in the assessment of freezing in Parkinson's disease patients. Ann Phys Rehabil Med 2015. [DOI: 10.1016/j.rehab.2015.07.176] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
12
|
Hinsinger G, Galéotti N, Nabholz N, Urbach S, Rigau V, Demattei C, Lehmann S, Camu W, Labauge P, Castelnovo G, Brassat D, Loussouarn D, Salou M, Laplaud D, Casez O, Bockaert J, Marin P, Thouvenot E. Chitinase 3-like proteins as diagnostic and prognostic biomarkers of multiple sclerosis. Mult Scler 2015; 21:1251-61. [DOI: 10.1177/1352458514561906] [Citation(s) in RCA: 102] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2014] [Accepted: 11/05/2014] [Indexed: 01/15/2023]
Abstract
Background: Despite sensitivity of MRI to diagnose multiple sclerosis (MS), prognostic biomarkers are still needed for optimized treatment. Objective: The objective of this paper is to identify cerebrospinal fluid (CSF) diagnostic biomarkers of MS using quantitative proteomics and to analyze their expression at different disease stages. Methods: We conducted differential analysis of the CSF proteome from control and relapsing–remitting MS (RRMS) patients followed by verification by ELISA of candidate biomarkers in CSF and serum in control, clinically isolated syndrome (CIS), RRMS and progressive MS (PMS) patients. Results: Twenty-two of the 527 quantified proteins exhibited different abundances in control and RRMS CSF. These include chitinase 3-like protein 1 (CHI3L1) and 2 (CHI3L2), which showed a strong expression in brain of MS patients, especially in astrocytes and microglial cells from white matter plaques. CSF and serum CHI3L1 levels increased with the disease stage and CIS patients with high CSF (>189 ng/ml) and serum (>33 ng/ml) CHI3L1 converted more rapidly to RRMS (log rank test, p < 0.05 and p < 0.001, respectively). In contrast, CSF CHI3L2 levels were lower in PMS than in RRMS patients. Accordingly, CSF CHI3L1/CHI3L2 ratio accurately discriminated PMS from RRMS. Conclusions: CSF CHI3L1 and CHI3L2 and serum CHI3L1 might help to define MS disease stage and have a prognostic value in CIS.
Collapse
Affiliation(s)
- G Hinsinger
- Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier 1, Université Montpellier 2, France
| | - N Galéotti
- Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier 1, Université Montpellier 2, France
| | - N Nabholz
- Service d’Ophtalmologie, Hôpital Gui de Chauliac, CHU de Montpellier, France
| | - S Urbach
- Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier 1, Université Montpellier 2, France
| | - V Rigau
- Service d’Anatomopathologie, Hôpital Gui de Chauliac, CHU de Montpellier, France
| | - C Demattei
- Département d’Information Médicale, CHU de Nîmes, France
| | - S Lehmann
- Service de Biochimie, Hôpital Gui de Chauliac, CHU de Montpellier, France
| | - W Camu
- Service de Neurologie, Hôpital Gui de Chauliac, CHU de Montpellier, France
| | - P Labauge
- Service de Neurologie, Hôpital Gui de Chauliac, CHU de Montpellier, France
| | - G Castelnovo
- Service de Neurologie, Hôpital Carémeau, CHU de Nîmes, France
| | - D Brassat
- Service de Neurologie, Hôpital Purpan, CHU de Toulouse, France
| | - D Loussouarn
- Service d’Anatomopathologie, CHU de Nantes, France
| | | | - D Laplaud
- INSERM 1064, France/Service de Neurologie, CHU de Nantes, France
| | - O Casez
- Service de Neurologie, CHU de Grenoble, France
| | - J Bockaert
- Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier 1, Université Montpellier 2, France
| | - P Marin
- Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier 1, Université Montpellier 2, France
| | - E Thouvenot
- Institut de Génomique Fonctionnelle, CNRS UMR 5203, INSERM U661, Université Montpellier 1, Université Montpellier 2, France/Service de Neurologie, Hôpital Carémeau, CHU de Nîmes, France
| |
Collapse
|
13
|
Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Costa GD, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D’Alfonso S, Alvarez-Cermeño JC, Kleinová P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martínez AD, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr KM, Galimberti D, Rejdak K, Lycke J, Frederiksen JL, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg RLP, Yaldizli Ö, Vécsei L, Kieseier BC, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar LM, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan SV, Giovannoni G. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. Mult Scler 2015; 21:1013-24. [DOI: 10.1177/1352458514568827] [Citation(s) in RCA: 196] [Impact Index Per Article: 21.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2014] [Accepted: 11/19/2014] [Indexed: 11/15/2022]
Abstract
Background and objective: We explored which clinical and biochemical variables predict conversion from clinically isolated syndrome (CIS) to clinically definite multiple sclerosis (CDMS) in a large international cohort. Methods: Thirty-three centres provided serum samples from 1047 CIS cases with at least two years’ follow-up. Age, sex, clinical presentation, T2-hyperintense lesions, cerebrospinal fluid (CSF) oligoclonal bands (OCBs), CSF IgG index, CSF cell count, serum 25-hydroxyvitamin D3 (25-OH-D), cotinine and IgG titres against Epstein-Barr nuclear antigen 1 (EBNA-1) and cytomegalovirus were tested for association with risk of CDMS. Results: At median follow-up of 4.31 years, 623 CIS cases converted to CDMS. Predictors of conversion in multivariable analyses were OCB (HR = 2.18, 95% CI = 1.71–2.77, p < 0.001), number of T2 lesions (two to nine lesions vs 0/1 lesions: HR = 1.97, 95% CI = 1.52–2.55, p < 0.001; >9 lesions vs 0/1 lesions: HR = 2.74, 95% CI = 2.04–3.68, p < 0.001) and age at CIS (HR per year inversely increase = 0.98, 95% CI = 0.98–0.99, p < 0.001). Lower 25-OH-D levels were associated with CDMS in univariable analysis, but this was attenuated in the multivariable model. OCB positivity was associated with higher EBNA-1 IgG titres. Conclusions: We validated MRI lesion load, OCB and age at CIS as the strongest independent predictors of conversion to CDMS in this multicentre setting. A role for vitamin D is suggested but requires further investigation.
Collapse
Affiliation(s)
- J Kuhle
- Blizard Institute, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, UK/ Departments of Neurology and Biomedicine, University Hospital Basel, University of Basel, Switzerland
| | - G Disanto
- Blizard Institute, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, UK
| | - R Dobson
- Blizard Institute, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, UK
| | - R Adiutori
- Blizard Institute, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, UK
| | - L Bianchi
- Blizard Institute, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, UK
| | - J Topping
- Blizard Institute, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, UK
| | - JP Bestwick
- Wolfson Institute of Preventive Medicine, Queen Mary University of London, Barts and the London School for Medicine and Dentistry, UK
| | - U-C Meier
- Blizard Institute, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, UK
| | - M Marta
- Blizard Institute, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, UK
| | - G Dalla Costa
- Department of Neurology and INSPE, Vita-Salute San Raffaele University, Scientific Institute San Raffaele, Italy
| | - T Runia
- Department of Neurology, Erasmus MC University Medical Center, The Netherlands
| | - E Evdoshenko
- Centre of Multiple Sclerosis, City Clinical Hospital#31, Russia
| | - N Lazareva
- Centre of Multiple Sclerosis, City Clinical Hospital#31, Russia
| | - E Thouvenot
- Institut de Génomique Fonctionelle, CNRS UMR5203, INSERM U661, Université Montpellier 1, Université Montpellier, France, and Hôpital Carémeau, France
| | - P Iaffaldano
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Italy
| | - V Direnzo
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Italy
| | - M Khademi
- Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Sweden
| | - F Piehl
- Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Sweden
| | - M Comabella
- Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Institut de Receca Vall d’Hebron (VHIR), Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Spain
| | - M Sombekke
- Departments of Neurology and Clinical Chemistry, MS Center, Neurocampus Amsterdam, VU University Medical Centre Amsterdam, The Netherlands and BioMS-eu network
| | - J Killestein
- Departments of Neurology and Clinical Chemistry, MS Center, Neurocampus Amsterdam, VU University Medical Centre Amsterdam, The Netherlands and BioMS-eu network
| | - H Hegen
- Department of Neurology, Innsbruck Medical University, Austria
| | - S Rauch
- Department of Radiology, Innsbruck Medical University, Austria
| | - S D’Alfonso
- Department of Health Sciences and IRCAD, Eastern Piedmont University, Italy
| | | | - P Kleinová
- Department of Neurology, Charles University in Prague, Czech Republic
| | - D Horáková
- Department of Neurology, Charles University in Prague, Czech Republic
| | - R Roesler
- Department of Neurology, CSF Laboratory and MS Outpatient Unit, University of Ulm, Germany
| | - F Lauda
- Department of Neurology, CSF Laboratory and MS Outpatient Unit, University of Ulm, Germany
| | - S Llufriu
- Center for Neuroimmunology and Department of Neurology. Institut d’investigacions Biomèdiques August Pi Sunyer (IDIBAPS) – Hospital Clinic of Barcelona, Spain
| | - T Avsar
- Dr Orhan Öcalgiray Molecular Biology-Biotechnology and Genetics Research Centre, Istanbul Technical University, Turkey
| | - U Uygunoglu
- Department of Neurology, Istanbul University, Turkey
| | - A Altintas
- Department of Neurology, Istanbul University, Turkey
| | - S Saip
- Department of Neurology, Istanbul University, Turkey
| | - T Menge
- Department of Neurology, Medical Faculty, Heinrich-Heine-University, Germany
| | - C Rajda
- Department of Neurology, University of Szeged, Hungary
| | | | - N Moll
- Pôle de Neurosciences Cliniques, Service de Neurologie, Centre de Résonance Magnétique Biologique et Médicale, Centre Hospitalier Universitaire Timone, Laboratoire d’histocompatibilité, Etablissement Français du Sang Alpes Méditerrannée, Aix Marseille Université, France
| | - M Khalil
- Department of Neurology, Medical University of Graz, Austria
| | - R Marignier
- Department of Neurology, Université de Lyon, Université Claude Bernard-Lyon 1, France
| | - I Dujmovic
- Clinic of Neurology, Belgrade University School of Medicine, Serbia
| | - H Larsson
- Unit of Functional Imaging, Glostrup Hospital, University of Copenhagen, Denmark
| | - C Malmestrom
- Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Sweden
| | - E Scarpini
- Neurology Unit, Dept. of Pathophysiology and Transplantation, University of Milan, Fondazione Cà Granda, IRCCS Policlinico
| | - C Fenoglio
- Neurology Unit, Dept. of Pathophysiology and Transplantation, University of Milan, Fondazione Cà Granda, IRCCS Policlinico
| | - S Wergeland
- KG Jebsen Centre for MS-Research, Department of Clinical Medicine, Haukeland University Hospital, University of Bergen, Norway
| | - A Laroni
- Department of Neurology, University of Genoa, Italy
| | - V Annibali
- Centre for Experimental Neurological Therapies, S. Andrea Hospital-site, Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Italy
| | - S Romano
- Centre for Experimental Neurological Therapies, S. Andrea Hospital-site, Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Italy
| | - AD Martínez
- Department of Neurology of Hospital Británico of Buenos Aires, Argentina
| | - A Carra
- Department of Neurology of Hospital Británico of Buenos Aires, Argentina
| | - M Salvetti
- Centre for Experimental Neurological Therapies, S. Andrea Hospital-site, Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University, Italy
| | - A Uccelli
- Department of Neurology, University of Genoa, Italy
| | - Ø Torkildsen
- KG Jebsen Centre for MS-Research, Department of Clinical Medicine, Haukeland University Hospital, University of Bergen, Norway
| | - KM Myhr
- Department of Neurology, University of Genoa, Italy
| | - D Galimberti
- Neurology Unit, Dept. of Pathophysiology and Transplantation, University of Milan, Fondazione Cà Granda, IRCCS Policlinico
| | - K Rejdak
- Department of Neurology, Medical University of Lublin, Poland
| | - J Lycke
- Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Sweden
| | - JL Frederiksen
- Department of Neurology, Glostrup Hospital, University of Copenhagen, Denmark
| | - J Drulovic
- Clinic of Neurology, Belgrade University School of Medicine, Serbia
| | - C Confavreux
- Department of Neurology, Université de Lyon, Université Claude Bernard-Lyon 1, France
| | - D Brassat
- Department of Neurology, University of Toulouse, France
| | - C Enzinger
- Department of Neurology, Medical University of Graz, Austria
| | - S Fuchs
- Department of Neurology, Medical University of Graz, Austria
| | - I Bosca
- MS Unit, Neurology Department, La Fe University and Polytechnic Hospital, Instituto de investigación Sanitaria La Fe, Spain
| | - J Pelletier
- Pôle de Neurosciences Cliniques, Service de Neurologie, Centre de Résonance Magnétique Biologique et Médicale, Centre Hospitalier Universitaire Timone, Laboratoire d’histocompatibilité, Etablissement Français du Sang Alpes Méditerrannée, Aix Marseille Université, France
| | - C Picard
- Pôle de Neurosciences Cliniques, Service de Neurologie, Centre de Résonance Magnétique Biologique et Médicale, Centre Hospitalier Universitaire Timone, Laboratoire d’histocompatibilité, Etablissement Français du Sang Alpes Méditerrannée, Aix Marseille Université, France
| | - E Colombo
- C. Mondino National Neurological Institute, Italy
| | - D Franciotta
- C. Mondino National Neurological Institute, Italy
| | - T Derfuss
- Departments of Neurology and Biomedicine, University Hospital Basel, University of Basel, Switzerland
| | - RLP Lindberg
- Departments of Neurology and Biomedicine, University Hospital Basel, University of Basel, Switzerland
| | - Ö Yaldizli
- Departments of Neurology and Biomedicine, University Hospital Basel, University of Basel, Switzerland
| | - L Vécsei
- Department of Neurology, University of Szeged, Hungary
| | - BC Kieseier
- Department of Neurology, Medical Faculty, Heinrich-Heine-University, Germany
| | - HP Hartung
- Department of Neurology, Medical Faculty, Heinrich-Heine-University, Germany
| | - P Villoslada
- Center for Neuroimmunology and Department of Neurology. Institut d’investigacions Biomèdiques August Pi Sunyer (IDIBAPS) – Hospital Clinic of Barcelona, Spain
| | - A Siva
- Department of Neurology, Istanbul University, Turkey
| | - A Saiz
- Center for Neuroimmunology and Department of Neurology. Institut d’investigacions Biomèdiques August Pi Sunyer (IDIBAPS) – Hospital Clinic of Barcelona, Spain
| | - H Tumani
- Department of Neurology, CSF Laboratory and MS Outpatient Unit, University of Ulm, Germany
| | - E Havrdová
- Department of Neurology, Charles University in Prague, Czech Republic
| | - LM Villar
- Department of Neurology and Immunology, Hospital Ramón y Cajal, Spain
| | - M Leone
- MS Centre, SCDU Neurology, Head and Neck Department, AOU Maggiore della Carità, Italy
| | - N Barizzone
- Department of Health Sciences and IRCAD, Eastern Piedmont University, Italy
| | - F Deisenhammer
- Department of Neurology, Innsbruck Medical University, Austria
| | - C Teunissen
- Departments of Neurology and Clinical Chemistry, MS Center, Neurocampus Amsterdam, VU University Medical Centre Amsterdam, The Netherlands and BioMS-eu network
| | - X Montalban
- Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Institut de Receca Vall d’Hebron (VHIR), Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Spain
| | - M Tintoré
- Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Institut de Receca Vall d’Hebron (VHIR), Hospital Universitari Vall d’Hebron, Universitat Autònoma de Barcelona, Spain
| | - T Olsson
- Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Sweden
| | - M Trojano
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari, Italy
| | - S Lehmann
- Institut de Génomique Fonctionelle, CNRS UMR5203, INSERM U661, Université Montpellier 1, Université Montpellier, France, and Hôpital Carémeau, France
| | - G Castelnovo
- Institut de Génomique Fonctionelle, CNRS UMR5203, INSERM U661, Université Montpellier 1, Université Montpellier, France, and Hôpital Carémeau, France
| | - S Lapin
- Centre of Multiple Sclerosis, City Clinical Hospital#31, Russia
| | - R Hintzen
- Department of Neurology, Erasmus MC University Medical Center, The Netherlands
| | - L Kappos
- Departments of Neurology and Biomedicine, University Hospital Basel, University of Basel, Switzerland
| | - R Furlan
- Department of Neurology and INSPE, Vita-Salute San Raffaele University, Scientific Institute San Raffaele, Italy
| | - V Martinelli
- Department of Neurology and INSPE, Vita-Salute San Raffaele University, Scientific Institute San Raffaele, Italy
| | - G Comi
- Department of Neurology and INSPE, Vita-Salute San Raffaele University, Scientific Institute San Raffaele, Italy
| | - SV Ramagopalan
- Department of Physiology, Anatomy and Genetics and Medical Research Council Functional Genomics Unit, University of Oxford, UK
| | - G Giovannoni
- Blizard Institute, Queen Mary University of London, Barts and The London School of Medicine and Dentistry, UK
| |
Collapse
|
14
|
Lionnet C, Carra C, Ayrignac X, Levade T, Gayraud D, Castelnovo G, Besson G, Androdias G, Vukusic S, Confavreux C, Zaenker C, De Seze J, Collongues N, Blanc F, Tranchant C, Wallon D, Hannequin D, Gerdelat-Mas A, Brassat D, Clanet M, Zephir H, Outteryck O, Vermersch P, Labauge P. [Cerebrotendinous xanthomatosis: a multicentric retrospective study of 15 adults, clinical and paraclinical typical and atypical aspects]. Rev Neurol (Paris) 2014; 170:445-53. [PMID: 24746394 DOI: 10.1016/j.neurol.2014.01.675] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2013] [Revised: 01/13/2014] [Accepted: 01/16/2014] [Indexed: 11/30/2022]
Abstract
INTRODUCTION Cerebrotendinous xanthomatosis, a metabolic leukodystrophy with an autosomal recessive inheritance, is secondary to deficiency of sterol 27-hydroxylase, an enzyme involved in cholesterol catabolism. Classical symptoms include clinical or infraclinical xanthomas affecting the skin and tendons, early cataracts, neurological signs and diarrhea. Brain imaging reveals involvement of the dentate nuclei and periventricular white matter hyperintensities. The diagnosis is based on an increased cholestanol level in serum, confirmed by the presence of a mutation in the CYP27A1 gene. Treatment is based on chenodeoxycholic acid. METHOD We report a retrospective multicentric study of 15 cases of cerebrotendinous xanthomatosis diagnosed in French adults. Clinical, molecular and MRI findings were recorded in all patients. RESULTS The average age at diagnosis was 39years (range 27-65). Disease onset occurred in childhood in 73% of patients and in adulthood in 27%. All patients with a pediatric onset were diagnosed during adulthood (age range 28-65years). Clinical symptoms variably associated cerebellar syndrome, pyramidal syndrome, cognitive decline, epilepsy, neuropathy (sought in 10 of our patients, present in forms in 8), psychiatric disorders, cataract and xanthomas. One patient had an atypical presentation: monoparesis associated with xanthomas. Brain MRI was abnormal in all: findings consisted in T2-weighted hyperintensity of the dentate nuclei (47%), periventricular leuoencephalopathy (73%) which preferentially involved the posterior cerebral part (60%), leucoencephalopathy with a vascular pattern (7%), hyperintensity of the cortico-spinal tracts (53%), globi pallidi, corpus callosum and cerebral atrophy (33%). Serum cholestanol was elevated in 93% of patients. The most frequent mutation was 1183C>T (n=5/15). Under treatment with chenodeoxycholic acid, eight patients improved initially, followed by stabilization in five of them, and worsening in the others. Four patients died. CONCLUSION Patients with the xanthoma-neurological disorder association should be tested for cerebrotendinous xanthomatosis. The disease often begins in childhood with a diagnostic delay but also in adulthood. Involvement of the dentate nuclei is specific but not sensitive and the supratentorial leucoencephalopathy is not specific but with an antero-posterior gradient. A vascular distribution and involvement of the corpus callosum are possible. Serum cholestanol assay is very reliable: an elevated level provides the diagnosis, which must nevertheless be confirmed by molecular biology.
Collapse
Affiliation(s)
- C Lionnet
- Service de neurologie, hôpital Gui-de-Chauliac, CHU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier, France
| | - C Carra
- Service de neurologie, hôpital Gui-de-Chauliac, CHU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier, France
| | - X Ayrignac
- Service de neurologie, hôpital Gui-de-Chauliac, CHU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier, France
| | - T Levade
- Laboratoire de biochimie, hôpital Rangueil, CHU de Toulouse, 1, avenue J.-Poulhès, 31403 Toulouse, France
| | - D Gayraud
- Service de neurologie, centre hospitalier du pays d'Aix, avenue des Tamaris, 13616 Aix-en-Provence cedex 1, France
| | - G Castelnovo
- Service de neurologie, hôpital Caremeau, CHU de Nîmes, place du Professeur-Debré, 30029 Nîmes cedex 4, France
| | - G Besson
- Service de neurologie, CHU de Grenoble, boulevard de la Chantourne, 38700 La Tronche, France
| | - G Androdias
- Service de neurologie, hôpital Pierre-Wertheimer, CHU de Lyon, 59, boulevard Pinel, 69500 Bron, France
| | - S Vukusic
- Service de neurologie, hôpital Pierre-Wertheimer, CHU de Lyon, 59, boulevard Pinel, 69500 Bron, France
| | - C Confavreux
- Service de neurologie, hôpital Pierre-Wertheimer, CHU de Lyon, 59, boulevard Pinel, 69500 Bron, France
| | - C Zaenker
- Cabinet privé, 64, rue Robert-Schuman, 68000 Colmar, France
| | - J De Seze
- Service de neurologie, hôpital de Hautepierre, CHU de Strasbourg, 1, avenue Molière, 67098 Strasbourg, France
| | - N Collongues
- Service de neurologie, hôpital de Hautepierre, CHU de Strasbourg, 1, avenue Molière, 67098 Strasbourg, France
| | - F Blanc
- Service de neurologie, hôpital de Hautepierre, CHU de Strasbourg, 1, avenue Molière, 67098 Strasbourg, France
| | - C Tranchant
- Service de neurologie, hôpital de Hautepierre, CHU de Strasbourg, 1, avenue Molière, 67098 Strasbourg, France
| | - D Wallon
- Service de neurologie, CHU de Rouen, 1, rue Germont, 70031 Rouen, France
| | - D Hannequin
- Service de neurologie, CHU de Rouen, 1, rue Germont, 70031 Rouen, France
| | - A Gerdelat-Mas
- Service de neurologie, hôpital Purpan, CHU de Toulouse, place du Docteur-Baylac, 31059 Toulouse cedex 9, France
| | - D Brassat
- Service de neurologie, hôpital Purpan, CHU de Toulouse, place du Docteur-Baylac, 31059 Toulouse cedex 9, France
| | - M Clanet
- Service de neurologie, hôpital Purpan, CHU de Toulouse, place du Docteur-Baylac, 31059 Toulouse cedex 9, France
| | - H Zephir
- Service de neurologie D, hôpital Roger-Salengro, CHU de Lille, avenue du Pr-Émile-Laine, 59037 Lille cedex, France
| | - O Outteryck
- Service de neurologie D, hôpital Roger-Salengro, CHU de Lille, avenue du Pr-Émile-Laine, 59037 Lille cedex, France
| | - P Vermersch
- Service de neurologie D, hôpital Roger-Salengro, CHU de Lille, avenue du Pr-Émile-Laine, 59037 Lille cedex, France
| | - P Labauge
- Service de neurologie, hôpital Gui-de-Chauliac, CHU de Montpellier, 80, avenue Augustin-Fliche, 34295 Montpellier, France.
| |
Collapse
|
15
|
Castelnovo G, Ratiu D, Taieb G. [Remote cerebellar hemorrhage following spinal surgery]. Rev Neurol (Paris) 2014; 170:467-8. [PMID: 24679483 DOI: 10.1016/j.neurol.2014.01.676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2013] [Revised: 01/01/2014] [Accepted: 01/04/2014] [Indexed: 11/19/2022]
Affiliation(s)
- G Castelnovo
- Service de neurologie, CHU Caremeau, place du Professeur-Debré, 30029 Nîmes cedex 9, France.
| | - D Ratiu
- Service de neurologie, CHU Caremeau, place du Professeur-Debré, 30029 Nîmes cedex 9, France
| | - G Taieb
- Service de neurologie, CHU Caremeau, place du Professeur-Debré, 30029 Nîmes cedex 9, France
| |
Collapse
|
16
|
Nerrant E, Charif M, Castelnovo G, Salsac C, Eliaou JF, Labauge P, Vincent T. Les anticorps anti-KIR4.1 sont-ils des biomarqueurs de la sclérose en plaques ? Rev Neurol (Paris) 2014. [DOI: 10.1016/j.neurol.2014.01.311] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
17
|
Corlobé A, Renard D, Goizet C, Berger E, Rumbach L, Robinson A, Dupuy D, Touzé E, Zéphir H, Vermersch P, Brochet B, Edan G, Deburghgraeve V, Créange A, Castelnovo G, Cohen M, Lebrun-Frenay C, Boespflug-Tanguy O, Labauge P. [Cavitary lesions in multiple sclerosis: multicenter study on twenty patients]. Rev Neurol (Paris) 2013; 169:965-9. [PMID: 24139243 DOI: 10.1016/j.neurol.2013.02.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2012] [Revised: 01/03/2013] [Accepted: 02/04/2013] [Indexed: 10/26/2022]
Abstract
INTRODUCTION Cavitary white matter changes are mainly described in leukodystrophies and especially in vanishing white matter disease. Large cavitary lesions are not typical for multiple sclerosis (MS). METHODS We studied MS patients with large cavitary brain lesions. Patient characteristics, disease onset/duration/subtype, expanded disability status scale (EDSS), mini mental state (MMS), vanishing white matter disease genetic analysis, and MRI characteristics of the cavitary lesions were analyzed. RESULTS Twenty patients were analyzed (6 men and 14 women). Mean age at disease onset was 37.6 (range 17-58). Mean disease duration was 10 years (range 2-20). Five patients had initial relapsing-remitting MS and nine patients had primary-progressive MS. Mean EDSS was 5.5 (range 2-8). Mean MMS was 20/30. Vanishing white matter disease genetic analysis was performed and negative in seven patients. Inferior corpus callosum lesions were seen in all patients with available sagittal FLAIR sequences. Cavitary lesions were strictly supratentorial, and located inside the diffuse leukoencephalopathy, with often a posterior predominance. CONCLUSION MS patients with large cavitary lesions seem to represent a MS subgroup, predominantly women, with relatively late disease onset, predominantly primary-progressive type, relatively high EDSS scores, and severe cognitive dysfunction.
Collapse
Affiliation(s)
- A Corlobé
- Service de neurologie, hôpital Gui-de-Chauliac, 80, avenue Augustin-Fliche, 34295 Montpellier cedex 5, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Outteryck O, Ongagna J, Brochet B, Rumbach L, Lebrun-Frenay C, Debouverie M, Zéphir H, Ouallet J, Berger E, Cohen M, Pittion S, Laplaud D, Wiertlewski S, Cabre P, Pelletier J, Rico A, Defer G, Derache N, Camu W, Thouvenot E, Moreau T, Fromont A, Tourbah A, Labauge P, Castelnovo G, Clavelou P, Casez O, Hautecoeur P, Papeix C, Lubetzki C, Fontaine B, Couturier N, Bohossian N, Clanet M, Vermersch P, de Sèze J, Brassat D. A prospective observational post-marketing study of natalizumab-treated multiple sclerosis patients: clinical, radiological and biological features and adverse events. The BIONAT cohort. Eur J Neurol 2013; 21:40-8. [DOI: 10.1111/ene.12204] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2013] [Accepted: 04/30/2013] [Indexed: 11/29/2022]
Affiliation(s)
- O. Outteryck
- Neurologie; Université de Lille Nord de France (EA2686); Hôpital Roger Salengro CHRU Lille; Lille France
| | | | - B. Brochet
- Neurologie; CHU Pellegrin; Bordeaux France
| | - L. Rumbach
- Neurologie; CHU Besançon; Besançon France
| | | | | | - H. Zéphir
- Neurologie; Université de Lille Nord de France (EA2686); Hôpital Roger Salengro CHRU Lille; Lille France
| | | | - E. Berger
- Neurologie; CHU Besançon; Besançon France
| | - M. Cohen
- Neurologie; Hôpital Pasteur; Nice France
| | | | | | | | - P. Cabre
- Neurologie; CHU Fort de France; Fort de France France
| | - J. Pelletier
- Neurologie; Hôpital de la Timone; Marseille France
| | - A. Rico
- Neurologie; Hôpital de la Timone; Marseille France
| | - G. Defer
- Neurologie; CHU Caen; Caen France
| | | | - W. Camu
- Neurologie; CHU Montpellier; Montpellier France
| | | | | | | | | | - P. Labauge
- Neurologie; CHU Montpellier; Montpellier France
| | | | - P. Clavelou
- Neurologie; CHRU Clermont Ferrand; Clermont Ferrand France
| | - O. Casez
- Neurologie; CHU Grenoble; Grenoble France
| | | | - C. Papeix
- Neurologie; Hôpital de la Salpêtrière; Paris France
| | - C. Lubetzki
- Neurologie; Hôpital de la Salpêtrière; Paris France
| | - B. Fontaine
- Neurologie; Hôpital de la Salpêtrière; Paris France
| | - N. Couturier
- Pole des neurosciences CHU Purpan; INSERM U1043; Toulouse France
| | - N. Bohossian
- Pole des neurosciences CHU Purpan; INSERM U1043; Toulouse France
| | - M. Clanet
- Pole des neurosciences CHU Purpan; INSERM U1043; Toulouse France
| | - P. Vermersch
- Neurologie; Université de Lille Nord de France (EA2686); Hôpital Roger Salengro CHRU Lille; Lille France
| | - J. de Sèze
- Neurologie; Hôpital Civil; Strasbourg France
| | - D. Brassat
- Pole des neurosciences CHU Purpan; INSERM U1043; Toulouse France
| | | |
Collapse
|
19
|
Castelnovo G, Renard D. Unmasking a subarachnoid hemorrhage. Neurology 2013; 80:2274. [DOI: 10.1212/wnl.0b013e318296e9e5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
20
|
Renard D, Collombier L, Castelnovo G, Boudusque V. La tomographie par émission de positons au fluorodéoxyglucose (FDG-TEP) dans la maladie de Creutzfeldt-Jacob sporadique. Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
21
|
Ratiu D, El Fertit H, Bouly S, Castelnovo G. L’hémorragie cérébelleuse à distance (HCD) du site de la chirurgie, à propos d’un cas. Rev Neurol (Paris) 2013. [DOI: 10.1016/j.neurol.2013.01.218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
22
|
de Verdal M, Renard D, Collombier L, Boudousq V, Kotzki PO, Labauge P, Castelnovo G. I123-FP-CIT single-photon emission tomography in patients with long-standing mixed tremor. Eur J Neurol 2012; 20:382-8. [DOI: 10.1111/j.1468-1331.2012.03875.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2012] [Accepted: 08/17/2012] [Indexed: 11/28/2022]
Affiliation(s)
- M. de Verdal
- Department of Neurology; CHU Caremeau; Nimes; France
| | - D. Renard
- Department of Neurology; CHU Caremeau; Nimes; France
| | - L. Collombier
- Department of Nuclear Medicine; CHU Caremeau; Nimes; France
| | - V. Boudousq
- Department of Nuclear Medicine; CHU Caremeau; Nimes; France
| | - P. O. Kotzki
- Department of Nuclear Medicine; CHU Caremeau; Nimes; France
| | - P. Labauge
- Department of Neurology; CHU Caremeau; Nimes; France
| | - G. Castelnovo
- Department of Neurology; CHU Caremeau; Nimes; France
| |
Collapse
|
23
|
Bourre B, Marignier R, Zéphir H, Papeix C, Brassat D, Castelnovo G, Collongues N, Vukusic S, Labauge P, Outteryck O, Fontaine B, Vermersch P, Confavreux C, de Seze J. Neuromyelitis optica and pregnancy. Neurology 2012; 78:875-9. [PMID: 22402855 DOI: 10.1212/wnl.0b013e31824c466f] [Citation(s) in RCA: 83] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE The purpose of our study was to assess the influence of pregnancy on the course of neuromyelitis optica (NMO) and the impact of epidural analgesia and breastfeeding on its activity in the postpartum period. METHODS We performed a retrospective study of patients with NMO diagnosed according to Wingerchuk criteria. We noted the number of relapses during the year before pregnancy (BP), during pregnancy (first trimester, second trimester, third trimester), and the year after (Y + 1: first trimester, second trimester [PP2], and third and fourth trimesters postpartum). Epidural analgesia and breastfeeding were recorded. Disability was evaluated with the Kurtzke Expanded Disability Status Scale (EDSS). The annualized relapse rate (ARR) was calculated. RESULTS We identified 124 patients (85 female) in the French NOMADMUS cohort on November 1, 2010. A total of 20 women (including 25 pregnancies) were informative with complete files. Comparisons between the ARR of each period and BP (1.0 ± 0.09) only showed an increased tendency for PP2 (0.8 ± 0.06, p = 0.07). Epidural analgesia and breastfeeding had no influence on the course of NMO. The EDSS score increased from 1.5 ± 1.7 BP to 2.6 ± 1.9 Y + 1 (p = 0.027). CONCLUSION This study shows that pregnancy influences the activity of NMO, a finding that justifies close medical monitoring. We found no evidence to suggest that either epidural analgesia or breastfeeding has an aggravating effect on NMO.
Collapse
Affiliation(s)
- B Bourre
- Department of Neurology, Hôpital Charles Nicolle, Rouen, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Ayrignac X, Taïeb G, Castelnovo G, Renard D, Collombier L, Menjot de Champfleur N, Labauge P. Cortical and cerebellar hypometabolism after bilateral antero-inferior cerebellar artery infarct. Neurology 2011; 78:69-70. [PMID: 22170886 DOI: 10.1212/wnl.0b013e31823ed128] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- X Ayrignac
- Neurology Department, CHU Nîmes, Hoˆpital Caremeau, Nîmes, France.
| | | | | | | | | | | | | |
Collapse
|
25
|
Renard D, Castelnovo G, Daubin D, Collombier L, Briere C, Labauge P. Teaching neuroimages: brain MRI and FDG-PET in malformations of cortical development and hippocampal hypoplasia. Neurology 2011; 77:e47. [PMID: 21860005 DOI: 10.1212/wnl.0b013e31822b0055] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- Dimitri Renard
- Department of Neurology, CHU Nîmes, Hôpital Caremeau, Nîmes, France.
| | | | | | | | | | | |
Collapse
|
26
|
Castelnovo G, Collombier L, Renard D, Labauge P. FDG-PET hypermetabolism in paraneoplastic cerebellar degeneration. Acta Neurol Belg 2011; 111:165. [PMID: 21748944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Affiliation(s)
- G Castelnovo
- Department of Neurology, CHU Nimes, Hopital Caremeau, Nimes cedex 4, France.
| | | | | | | |
Collapse
|
27
|
Taieb G, Wacongne A, Renard D, Figarella-Branger D, Castelnovo G, Labauge P. A new case of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids with initial normal magnetic resonance imaging. Brain 2011; 134:e182; author reply e183. [DOI: 10.1093/brain/awq390] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Collongues N, Marignier R, Zéphir H, Papeix C, Blanc F, Ritleng C, Tchikviladzé M, Outteryck O, Vukusic S, Fleury M, Fontaine B, Brassat D, Clanet M, Milh M, Pelletier J, Audoin B, Ruet A, Lebrun-Frenay C, Thouvenot E, Camu W, Debouverie M, Créange A, Moreau T, Labauge P, Castelnovo G, Edan G, Le Page E, Defer G, Barroso B, Heinzlef O, Gout O, Rodriguez D, Wiertlewski S, Laplaud D, Borgel F, Tourniaire P, Grimaud J, Brochet B, Vermersch P, Confavreux C, de Seze J. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 2010; 74:736-42. [PMID: 20194912 DOI: 10.1212/wnl.0b013e3181d31e35] [Citation(s) in RCA: 158] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND There have been few epidemiologic studies on neuromyelitis optica (NMO) and none used the recent 2006 diagnostic criteria. Here we describe the clinical, laboratory, MRI, and disability course of NMO in a French cohort of 125 patients. METHODS We performed an observational, retrospective, multicenter study. Data were collected from September 2007 through August 2008, corresponding to the endpoint of the study. We identified 125 patients fulfilling the 2006 NMO criteria. Selection was made using hospital files and a specific clinical questionnaire for NMO. RESULTS Mean age at onset was 34.5 years (range 4-66) with a mean disease duration of 10 +/- 7.8 years at the endpoint. The patients were mainly (87%) Caucasian, with a female:male ratio of 3:1. In 90% of cases, the association of optic neuritis, longitudinal extensive myelitis, and a Paty-negative initial brain MRI was sufficient to fulfill the supportive criteria. Eighty-eight percent of patients were treated with immunosuppressive therapies. Median delay from onset to Expanded Disability Status Scale (EDSS) score 4 was 7 years; score 6, 10 years; and score 7, 21 years. The first episode of myelitis was immediately followed by an EDSS score > or = 4 in 37.3% of cases, and a severe residual visual loss was observed in 22% of patients after the first episode of optic neuritis. Multivariate analysis did not reveal any predictors of a poor evolution other than a high number of MRI brain lesions at diagnosis, which were predictive of a residual visual acuity < or = 1/10. CONCLUSIONS Our demographic data provide new data on disability in patients with neuromyelitis optica, most of whom were receiving treatment.
Collapse
Affiliation(s)
- N Collongues
- Department of Neurology, University Hospital of Strasbourg, 67091 Strasbourg, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
de Verdal M, Castelnovo G, Renard D, Labauge P. P1.108 Periaqueductal T2-weighted MRI hyperintensity in early stage progressive supranuclear palsy. Parkinsonism Relat Disord 2009. [DOI: 10.1016/s1353-8020(09)70230-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Castelnovo G, Collombier L, Renaud S, de Verdal M, Renard D, Kotzki J, Labauge P. P1.197 Presynaptic dopaminergic dysfunction on [123I]-FP-CIT SPECT in patients with long standing essential tremor with associated rest tremor. Parkinsonism Relat Disord 2009. [DOI: 10.1016/s1353-8020(09)70319-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
31
|
Pers YM, Taïeb G, Ayrignac X, Castelnovo G, Hubert AM, Boucraut J, Labauge P. GQ1b ganglioside antibody-related disorders: a case with a complex phenotype. Acta Neurol Belg 2009; 109:330-332. [PMID: 20120217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
We described an overlap syndrome associating Miller Fisher syndrome (MFS) and acute inflammatory demyelinating polyradiculoneuropathy (AIDP). Furthermore, the patient presented unusual neurological manifestations including headache, T10 sensory level, urinary urgency, and gadolinium enhancement of the spinal roots. One year follow-up was characterized by clinical recovery and persistent high rates of anti-GQ1b, -GD1b and -GT1b antibodies. Our case suggests broad phenotype of persistent antigangliosides antibodies.
Collapse
Affiliation(s)
- Y M Pers
- Department of Neurology, Caremeau Hospital, CHU Nîmes, France
| | | | | | | | | | | | | |
Collapse
|
32
|
Versino M, Bergamaschi R, Callieco R, Romani A, Castelnovo G, Beltrami G, Cosi V. Eye movement quantitative evaluation before and after high-dose 6-methylprednisolone in multiple sclerosis. Acta Neurol Scand 2009. [DOI: 10.1111/j.1600-0404.1994.tb01644.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
33
|
Collongues N, Marignier R, Zéphir H, Papeix C, Blanc F, Tchikviladzé M, Ritleng C, Outteryck O, Vukusic S, Fleury M, Mignot C, Brassat D, Clanet M, Milh M, Ruet A, Lebrun-Frenay C, Camu W, Debouverie M, Créange A, Moreau T, Labauge P, Castelnovo G, Edan G, Lepage E, Defer G, Barroso B, Thouvenot E, Heinzlef O, Gout O, Rodriguez D, Augustin J, Wiertlewski S, Laplaud D, Borgel F, Slassi I, Berroir S, Tourniaire P, Grimaud J, Brochet B, Vermersch P, Confavreux C, de Sèze J. Neuromyélite optique de Devic et patients à haut risqué : enquête rétrospective nationale. Rev Neurol (Paris) 2009. [DOI: 10.1016/s0035-3787(09)70025-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
34
|
Renard D, Castelnovo G, Jeanjean L, Perrochia H, Brunel H, Labauge P. Teaching NeuroImage: Microangiopathic complications in pseudoxanthoma elasticum. Neurology 2008; 71:e69. [DOI: 10.1212/01.wnl.0000335934.11120.83] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
35
|
Arndt C, Labauge P, Speeg-Schatz C, Jeanjean L, Fleury M, Castelnovo G, Ballonzolli L, Blanc F, Carlander B, De Sèze J. [Recurrent inflammatory optic neuropathy]. J Fr Ophtalmol 2008; 31:363-7. [PMID: 18563035 DOI: 10.1016/s0181-5512(08)71430-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
PURPOSE To analyze clinical and paraclinical characteristics of recurrent isolated optic neuropathy. PATIENTS and method: In three university hospitals (Montpellier, Nimes, and Strasbourg), between October 2005 and September 2006, the charts of patients with corticosensitive recurrent isolated optic neuropathy and normal cerebral magnetic resonance imaging included prospectively were reviewed. The following parameters were analyzed: date of the first relapse, age at onset, duration at the time of inclusion, recurrence after steroid withdrawal, unilateral or bilateral involvement, number of relapses, visual acuity, retinal nerve fiber layer thickness, diagnostic workup, and long-term treatment with immunosuppressive or immunomodulatory drugs. RESULTS During the predefined period, 13 patients (11 women, 2 men; age, 17-54 years at onset) matched the inclusion criteria. Between two and six relapses of optic neuropathy were observed. The median duration was 4 years. In untreated patients (n=7), a significant (Spearman p=0.0156) inverse correlation was observed between visual acuity and duration of the disease; this correlation was not found in the group of patients (n=6) with long-term treatment (Spearman p=0.1032). CONCLUSION The progressive loss of vision over time in this retrospective study of recurrent isolated optic neuropathy could be related to axonal loss. A prospective cohort study is necessary to confirm this hypothesis and to evaluate the benefit of long-term treatment on this progression.
Collapse
Affiliation(s)
- C Arndt
- Service d'Ophtalmologie, Hôpital Gui de Chauliac, CHU, Montpellier.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Jeanjean L, Castelnovo G, Carlander B, Villain M, Mura F, Dupeyron G, Labauge P. [Retinal atrophy using optical coherence tomography (OCT) in 15 patients with multiple sclerosis and comparison with healthy subjects]. Rev Neurol (Paris) 2008; 164:927-34. [PMID: 18808761 DOI: 10.1016/j.neurol.2008.03.008] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2007] [Revised: 03/01/2008] [Accepted: 03/20/2008] [Indexed: 01/21/2023]
Abstract
INTRODUCTION Multiple sclerosis is a common disabling progressive neurological disorder. Axonal loss is thought to be a likely cause of persistent disability after a multiple sclerosis relapse. Retinal nerve fiber layer (RNFL) imaging by optical coherence tomography (OCT) seems to be a non-invasive way of detecting optical axonal loss following optic neuritis. OBJECTIVE To determine whether multiple sclerosis affects retinal nerve fiber layer measurements obtained with optical coherence tomography (OCT3-Carl Zeiss Meditec, Dublin, California, USA). MATERIAL AND METHODS Diagnosis of MS was based on the MacDonald criteria. The cohort was divided into two groups based on their clinical course (multiple sclerosis with [n=8; 16 eyes] or without [n=7; 14 eyes] optic neuritis antecedents). The disease-free controls were matched for age and gender (n=15; 30 eyes). Retinal nerve fiber layer thickness was measured using optical coherence tomography (OCT; fastRNFL and RNFL thickness software protocol). Visual acuity, visual field, color vision were also noted. RESULTS There were highly significant reductions (p<0.001) of retinal nerve fiber layer thickness in affected patients (with or without optic neuritis antecedents) compared with control eyes (fastRNFL and RNFL procedures). Visual acuity, visual field and color vision were globally less altered than OCT. There were no significant relationships among RNFL thickness and visual acuity, visual field, or color vision. CONCLUSION This study has demonstrated the anatomic changes of the retinal nerve fiber layer of patients with multiple sclerosis with optic neuritis antecedents. Thus axonal loss following optic neuritis can be detected with OCT. But the retinal nerve fiber layer of patients without optic neuritis is also thinner than disease-free controls so that chronic optic axonal loss can be frequent in multiple sclerosis. Additionally, OCT was more sensitive than the common ophthalmological explorations to detect optical nerve impairment during multiple sclerosis. Finally, we demonstrated that two procedures fastRNFL and RNFL could be used to detect optic nerve impairment.
Collapse
Affiliation(s)
- L Jeanjean
- Consultation de neuro-ophtalmologie, CHU Carémeau, place du Professeur-Debré, 30900 Nîmes, France.
| | | | | | | | | | | | | |
Collapse
|
37
|
Landragin N, Jeanjean L, Bouly S, Honnorat J, de Sèze J, Castelnovo G, Labauge P. [Devic disease associated with isolated spinal cord atrophy]. Rev Neurol (Paris) 2008; 163:1236-8. [PMID: 18355472 DOI: 10.1016/s0035-3787(07)78409-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
Devic disease is a rare entity characterized by bilateral optic neuritis and transverse myelitis. Recently, recognition of antibody activity (Anti NMO) led to broaden the clinical and MR phenotype spectrum of this disease. This report is about a patient with spinal cord atrophy and bilateral optic neuritis, occurring more than 8 years after symptom onset.
Collapse
|
38
|
Castelnovo G, Levade T, Riise Stensland HMF, Nonnon MJ, Berges MA, Tollersrud OK, Labauge P. [Adult leukoencephalopathy caused by alpha-mannosidosis deficiency]. Rev Neurol (Paris) 2007; 163:359-61. [PMID: 17404523 DOI: 10.1016/s0035-3787(07)90408-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Adult leukoencephalopathy caused by alpha-mannosidosis deficiency (MIM248500) is a recessive inherited lysosomal storage disease associated with decreased activity of alpha-mannosidase. This enzyme degrades oligosaccharides and glycoproteins in neural and visceral tissues. There are two different disease phenotypes, type-I or severe infantile phenotype and type 2, which progresses more slowly and is compatible with survival into adulthood. We report the case of a 51-year-old man with gait disorders beginning at the age of 40 years associated with leukoencephalopathy due to alpha-mannosidosis deficiency.
Collapse
|
39
|
Abstract
Spinocerebellar ataxia type 7 (SCA 7) is a rare autosomal dominant neurodegenerative disorder (ADCA) caused by expansion of a highly unstable CAG repeat. Clinical features including progressive cerebellar, retinal degeneration and pyramidal signs. We report a patient with SCA 7 diagnosis revealed by progressive cerebellar ataxia and writer's cramp.
Collapse
Affiliation(s)
- N Gaillard
- Service de Neurologie - Centre Hospitalier Universitaire de Nîmes, Hôpital Caremeau 30029 Nîmes
| | | | | | | |
Collapse
|
40
|
Dutray A, Castelnovo G, Bouly S, Chabriat H, Bousser M, Labauge P. G - 25 Prévalence de la maladie de CADASIL et formes atypiques. Rev Neurol (Paris) 2007. [DOI: 10.1016/s0035-3787(07)90531-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
41
|
De Seze J, Blanc F, Zephir H, Lebrun C, Labauge P, Castelnovo G, Fleury M, Sellal F, Tranchant C, Dujardin K, Vermersch P. F - 10 Troubles cognitifs au cours de la neuro-myélite optique de Devic : étude prospective de 30 patients. Rev Neurol (Paris) 2007. [DOI: 10.1016/s0035-3787(07)90842-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
42
|
Jeanjean L, Godard A, Castelnovo G, Dupeyron G, Labauge P. Myosite orbitaire chez une femme enceinte : à propos d’un cas. Rev Neurol (Paris) 2007. [DOI: 10.1016/s0035-3787(07)90931-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
43
|
Gaillard N, Fabro-Perray P, Faillie JL, Le Bayon A, Castelnovo G, Dupeyron A, Froger J, Pelissier J, Labauge P. Influence des poussées sur la survenue d’un handicap au long cours dans la sclérose en plaques de forme rémittente : étude observationnelle de 99 patients. Rev Neurol (Paris) 2007; 163:72-81. [PMID: 17304175 DOI: 10.1016/s0035-3787(07)90357-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
INTRODUCTION Rate of relapse occurring during the first 5 years of MS-RR is a prognosis factor of occurrence of disability or secondary progressive (SP) phase. Progressive phase, related to chronic axonal loss, is mainly considered as the principal factor of disability progression. Influence of acute relapses during the relapsing-remitting phase on disability development is not known as a prognosis factor. OBJECTIVES To determine the influence of the exacerbations among patients with RR-MS after the second clinical event on the disability occurrence. METHODS Diagnosis of multiple sclerosis was established according to Poser's classification. Disability measurement was made with the use of the Expanded Disability Status Scale (EDSS). The patients included in the study were classified as clinically definite RR-MS, with an EDSS score<or=3.5. The progressive phase was defined as the steady worsening of symptoms and signs for at least 6 months (Schumacher et al., 1965; Lublin and Reingold, 1996). The exacerbations were quoted and evaluated by a neurologist and the residual disability lasting at least 6 months after an acute event was measured with the EDSS. A score of 4.0 corresponds to limited walking ability, but without aid or rest for>500 m. The study began at the time of the second clinical event and ended when an EDSS score of 4.0 was reached or when a SP phase was beginning or at the last follow-up visit date if these two stages were not reached. The primary outcome measure was the comparison of the risk and the average time to reach an EDSS>or=4.0 or a SP form according to the annual exacerbation rate (AER) using Kaplan-Meier survival curve. RESULTS Among the 238 ms patients of the database, 136 patients were classified as having a definite RR-MS. Among these 136 patients, 99 patients could be included in the study according to the inclusion criteria. The median follow up of the patients since the first clinical event was 9.8 years (range 4 to 44). The average EDSS score was 0.7 at the beginning of the study and 2.3 at the end. 20.2p.cent of patients (n=20) reached an EDSS score of 4.0 or a SP-MS. The median AER was 0.4 and the average 0.62 (range 0 to 6.1). The time to reach the primary end point for 25p.cent of the population was 17.8 years in group with an AER<0.4 (group A) and 6.9 years in group with an AER>0.4 (group B) (logrank; p<0.0001). The relative risk for patients of the group B compared to group A to reach an EDSS of 4.0 or a SP form was 8.01 (IC-95p.cent: 2.74-23.46; p=0.0001). CONCLUSIONS In spite of a limited number of patients, this study gives evidence that a high rate of acute exacerbations in RR-MS patients after the second clinical event may be an independent predictive factor of long-term residual disability progression. High relapse rate leads to a more frequent and faster SP or EDSS>4.0 occurrence.
Collapse
Affiliation(s)
- N Gaillard
- Service de Neurologie, CHU Carémeau, Nîmes
| | | | | | | | | | | | | | | | | |
Collapse
|
44
|
Fraisse T, Arnaud E, Castelnovo G, Balducchi JP, de Wazières B. Un Diagnostic vitE fait. Rev Med Interne 2006. [DOI: 10.1016/j.revmed.2006.10.181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
45
|
Bouzgarou E, Dupeyron A, Castelnovo G, Boudousq V, Collombier L, Labauge P, Pélissier J. [Camptocormia disclosing Parkinson's disease]. ACTA ACUST UNITED AC 2006; 50:55-9. [PMID: 17027115 DOI: 10.1016/j.annrmp.2006.07.060] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2006] [Accepted: 07/26/2006] [Indexed: 11/25/2022]
Abstract
Camptocormia is characterised as an extreme bent-forward posture of the trunk that disappears in the recumbent position. On X-ray, trunk flexion appears without vertebral rotation as in scoliosis. The condition is a well-known complication of Parkinson's disease (PD) at the late stage. The authors present the case of a 77-year-old woman affected by severe camptocormia, which appeared and worsened in less than 6 months and hindered gait. Despite no signs of PD, neuro-imaging (DAT-Scan) showed an L-Dopa transducer decrease in putamens. A few weeks later, bradykinesia appeared and the clinical diagnosis of PD became more obvious. L-Dopa improved bradykinesia but did not change the bent-spine posture. A 1-year follow-up showed no other signs of PD other than bradykinesia, but the camptocormia was unchanged.
Collapse
Affiliation(s)
- E Bouzgarou
- Département de MPR, groupe hospitalier Carémeau, 30029 Nîmes cedex 04, France
| | | | | | | | | | | | | |
Collapse
|
46
|
Affiliation(s)
- S Castro
- Neurological Department, Hopital Caremeau, CHU Nimes, Nimes, France
| | | | | | | | | | | |
Collapse
|
47
|
Pelissier J, Benaim C, Bonin-Koang KY, Castelnovo G, Perennou D. [Assessment of idiopathic Parkinson's disease in physical medicine and rehabilitation]. Ann Readapt Med Phys 2005; 48:341-5. [PMID: 15932779 DOI: 10.1016/j.annrmp.2005.04.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/04/2005] [Accepted: 04/04/2005] [Indexed: 05/02/2023]
Abstract
Parkinson's disease (PD) is a chronic disease associated with motor impairments (bradykinesia, rigidity, tremor and postural disorders), cognitive disorders and dysautonomia. Most symptoms are greatly improved by dopatherapy during the first stages, then signs of treatment ineffectiveness or intolerance occur that signal the beginning of motor and cognitive decline. This evolution signified the need to develop an effective tool to measure the effectiveness of drugs or surgery in PD and has had the Movement Disorder Society to propose 20 years ago a tool to assess such patients: the Unified Parkinson's Disease Rating Scale (UPDRS). This scale has a good internal consistency and a good interrater reliability. Yet, some impairments, especially of cognitive origin, are evaluated too succinctly and need complementary scales. As well, other disorders such as bladder disorders are not included, nor is quality of life studied despite the impact of PD on daily life. Specific scales have been proposed. UPDRS may be well-adapted to PD follow-up in the physical medicine and rehabilitation context by measuring treatment effectiveness, detecting Dopa ineffectiveness or complications and assessing patients' handicap in daily activities. The evolution of UPDRS will improve the qualities of the scale and contribute to better determining the various stages of the disease.
Collapse
Affiliation(s)
- J Pelissier
- Unité de rééducation neurologique, département de médecine physique et de réadaptation, CHU de Nîmes, 30240 le-Grau-du-Roi, France.
| | | | | | | | | |
Collapse
|
48
|
Bouly S, Le Bayon A, Blard JM, Touzé E, Leys D, Mas JL, Neau JP, Dauzat M, Gautier V, Delhaume O, Castelnovo G, Labauge P. Thrombus endoluminal de l’artère carotide sans lésion sous-jacente. Rev Neurol (Paris) 2005; 161:61-6. [PMID: 15678002 DOI: 10.1016/s0035-3787(05)84974-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Strokes are rarely secondary to spontaneous carotid artery thrombosis. The objectives of this retrospective analysis were to define characteristic features and the clinical course. The study population included eight patients (6 females/2 males) seen at six university neurological centers. Age of onset was 46.5 years (range 38-52). Half of the patients had no vascular risk factor. Symptoms were TIA (n=1), strokes (n=7). Echotomography revealed intraluminal thrombus, with occlusion in 2 cases. Thrombi were found in common carotid artery (n=3), carotid bifurcation (n=2) and internal carotid artery (n=3). The thrombus was mobile in 4 cases. Seven patients were treated by anticoagulation therapy, one by surgery because of recurrent TIA. Further echotomographic exams revealed total resolution (3 cases) or decrease of the thrombus (3 cases). Occlusion was definitive in one patient. A cause was identified in six patients: acute leukemia (n=1), thrombocytopenic purpura (n=1), iron deficiency anemia (n=4).
Collapse
Affiliation(s)
- S Bouly
- Service de Neurologie, Groupe Hospitalo-Universitaire Carémeau, CHU de Nîmes, Nîmes
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Affiliation(s)
- G Castelnovo
- Department, Hôpital Caremeau, CHU Nimes, 2 Av. du prof Debrie, Nimes, France.
| | | | | | | | | | | |
Collapse
|
50
|
Affiliation(s)
- G Castelnovo
- Department of Neurology, Caremeau Hospital, CHU Nimes, France.
| | | | | |
Collapse
|